Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 10, 2025Therapeutic Drug MonitoringOpen Access

Population Pharmacokinetic/Pharmacodynamic Model of the Impact of Cumulative Tacrolimus Exposure on Kidney Function After Liver Transplant

View Full Paper
Ask AI
Bookmark
Share

Authors

NTNingjia TangSMS. MaedaMOMasahiro Okuda

Discussion

Loading...

Member takes

Overview

Population pharmacokinetic model shows tacrolimus exposure predicts kidney function decline in liver transplant recipients, indicating nephrotoxicity risk.

Key Points

  • To develop a population pharmacokinetic/pharmacodynamic model assessing tacrolimus impact on kidney function post-liver transplant.
  • Retrospective analysis of adult liver transplant data
  • Nonlinear mixed-effects modeling approach used
  • Evaluation of tacrolimus trough concentrations and cumulative AUC metrics
  • Cumulative AUC over 3 months significantly associated with renal function decline
  • Best PK model fit provided by a one-compartment model
  • Clearance influenced by hematocrit and postoperative days within the first 14 days

Cite This Study

Tang et al. (2025) studied this question.

synapsesocial.com/papers/69401b3d2d562116f28f822ahttps://doi.org/10.1097/ftd.0000000000001418
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Population pharmacokinetics of tacrolimus and CYP3A5-driven variability: implications for model-informed dose individualization in pediatric renal transplant recipients2026
  2. 2Guiding the starting dose of the once-daily formulation of tacrolimus in “de novo” adult renal transplant patients: a population approach2024 · 3 citations
  3. 3Prediction of the Intra‐T Lymphocyte Tacrolimus Concentration after Kidney Transplantation with Population Pharmacokinetic Modeling2024 · 6 citations
  4. 4Population Pharmacokinetic/Pharmacodynamic Modeling of Tacrolimus in Renal Transplant Recipients: Impact of CYP3A5 Genotype and Wuzhi Capsule Co-Medication2025
  5. 5Population pharmacokinetic characteristics of tacrolimus in Chinese lung transplant recipients and optimisation of dosing regimen during the early post-transplantation phase2025 · 1 citations